FDA approves Moderna’s mRNA flu shot for adults 50+, signaling a new vaccine era
TL;DR Summary
FDA approval grants Moderna’s mRNA influenza shot, mFLUSIVA (mRNA-1010), for adults 50 and up, marking the first mRNA flu vaccine and following a unanimous June advisory panel vote citing strong efficacy and safety in about 44,000 people. The path to approval was politically tense due to anti-vaccine motivations within the Kennedy administration, and questions remain about ACIP recommendations, coverage, and near-term sales expectations, with Moderna aiming for the 2026–27 season.
- Moderna’s mRNA flu shot earns FDA approval after rollercoaster review Ars Technica
- What to know about the first mRNA-based flu shot approved by the FDA The Washington Post
- F.D.A. Approves Moderna’s mRNA Flu Vaccine The New York Times
- A new flu vaccine geared to older people is coming soon NPR
- One year since Kennedy canceled mRNA vaccine projects, science shows how wrong he was STAT
Reading Insights
Total Reads
0
Unique Readers
5
Time Saved
11 min
vs 12 min read
Condensed
97%
2,319 → 70 words
Want the full story? Read the original article
Read on Ars Technica